Efficacy and Safety for Use Desloratadine in Children with Allergic Conditions (Literature Review, Own Research)

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: Mar 15, 2021
DOI: https://doi.org/10.30841/2307-5112.5-6.2020.225468
Keywords:
children, allergic disease, treatments, antihistamine drugs, desloratadine (Edem),

##plugins.themes.bootstrap3.article.main##

Yurii Marushko
Bogomolets National Medical University, Ukraine
https://orcid.org/0000-0001-8066-9369
Olha Khomych
Bogomolets National Medical University, Ukraine
https://orcid.org/0000-0001-9272-7159

Abstract

According to scientists, more than 20 thousand allergens are known and their number is constantly increasing. Therefore, children’s allergy remains one of the urgent problems of modern medicine, since allergic diseases in adults in most cases begin from childhood.


The article summarizes our own data and presents a scientific review of the medical literature, which is devoted to the analysis of the problem of treatment of allergic diseases with desloratadine in children. Nowdays there is a significant prevalence of allergic conditions in children. We analyzed the effect of desloratadine on the course of allergic diseases in children. The analyzed literature review showed a high safety profile of the drug desloratadine. Also we presented the personal data of desloratadine therapy for seasonal allergic rhinitis in children.


The literature data presented in the article and our own experience allow us to conclude that allergic conditions remain an urgent problem in clinical medicine, and the use of antihistamines, in particular desloratadine, increases the effectiveness of allergy therapy and accelerates the recovery and disappearance of symptoms.

##plugins.themes.bootstrap3.article.details##

How to Cite
Marushko, Y., & Khomych, O. (2021). Efficacy and Safety for Use Desloratadine in Children with Allergic Conditions (Literature Review, Own Research). Family Medicine, (5-6), 84–88. https://doi.org/10.30841/2307-5112.5-6.2020.225468
Issue
No. 5-6 (2020)
Section
Lectures and reviews
Copyright (c) 2020 Yurii Marushko, Olha Khomych

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

Yurii Marushko, Bogomolets National Medical University

Yurii V. Marushko,

Head of Department of Pediatrics at the Institute of Postgraduate Education

Olha Khomych, Bogomolets National Medical University

Olha V. Khomych,

Department of Pediatrics at the Institute Postgraduate Education

References

Швецова Е.С., Короткова Т.С. Распространенность аллергических заболеваний среди всех возрастных групп населения Липецкой области. Современные проблемы науки и образования. 2017. № 4. С. 45–51.

Беш Л.В. Алергічний риніт у дітей. Здоровье ребенка. 2012. № 5 (40). С. 35–37.

Марушко Ю.В., Московенко О.Д. Комплексні препарати в терапії гострого риніту у дітей. Современная педиатрия. 2016. № 2 (74). С. 84–88.

Эрназарова Х., Хумроевна А. Распространенность аллергических заболеваний в мире. International scientific review. 2017. № 3. С. 15–19.

Гущин И.С., Курбачева О.М. Аллергия и аллерген-специфическая иммунотерапия. Фармарус Принт Медиа. 2010. С. 228.

25-й ежегодный Конгресс ЕААСІ (Вена, Австрия, 10–14 июня 2006 г.) «Аллергический ринит» // Клінічна імунологія. Алергологія. Інфектологія. 2006. № 2 (03). С. 62–64.

Мурзина Э.А. Современные антигистаминные препараты в лечении заболеваний аллергической природы. Внутренняя медицина. 2008. № 3 (9). С. 20–25.

Савченко В. Эффективность и безопасность дезлоратадина у детей. Обзор доказательной базы. Здоров’я України. 2011. № 2 (17). C. 47.

Гущин И.С. Перспективы совершенствования противоаллергического действия Н1-антигистаминных препаратов. Леч. врач. 2009. № 5. С. 34–40.

Марушко Ю.В., Московенко О.Д. Характеристика сенсибілізації і досвід використання дезлоратадину в лікуванні сезонного алергічного риніту в дітей. Здоровье ребенка. 2019. № 7. С. 54–57.

Niu S, Li Y, Dong W, Xia L, Shen T, Wang J, at all. A randomized study on the bioequivalence of desloratadine in Chinese healthy subjects and the association of different metabolic phenotypes with UGT2B10 and CYP2C8 genotypes. Curr Drug Metab. 2020. P. 1031–1039.

Molimard M., Diquet B. Benedetti M.S. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 2004. № 18. P. 399–411.

Bartra J., Valero A.L., Cuvillo A., Dávila I. Interactions of the H1 antihistamines. J. Investig. Allergol. Clin. Immunol. 2006. № 16. Р. 29–36.

Berginc К., Sibinovska N., Žakelj S., Trontelj J., Legen I. Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way. Acta Pharmaceutica. 2020. V. 70. Issue 2.

Kreutner W, Hey J.A., Anthes J., Barnett A., Young S., Tozzi S. Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects. Arzneimittelforschung. 2000. №50. Р. 345–352.

Andersson N.W., Poulsen H.E., Andersen J.T.J. Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study. Allergy Clin Immunol Pract. 2020. №8(5). Р. 1598–1605.

Ma J., Qi J., Li S., Zhang C., Wang H., Shao L., Yuan X., Sha Q. Desloratadine, a Novel Antigrowth Reagent for Bladder Cancer. Technol Cancer Res Treat. 2020. № 2. Р. 123–132.

Geha R.S., Meltzer E.O. Desloratadine: A new, nonsedating, oral antihistamine. Allergy Clin Immunol. 2001. № 107(4). Р. 751–62.

Jie Q., Kodithuwakku N.D., Yuan X., He G., Chen M., Xu S., Wu Y., Eur J. Antiallergic and anti-inflammatory properties of a potent histamine H1 receptor antagonist, desloratadine citrate disodium injection, and its anti-inflammatory mechanism on EA.hy926 endothelial cells. Pharmacol. 2015 № 5. Р. 1–10.

Uehara S., Yoneda N., Higuchi Y., Yamazaki H., Suemizu H. Metabolism of desloratadine by chimeric TK-NOG mice transplanted with human hepatocytes. Xenobiotica. 2020. № 50 (6). Р. 733–740.

Meltzer E.O., Prenner B.M., Nayak A. Efficacy and tolerability of once-daily 5 mg desloratadine, an h1-receptor antagonist, in patients with seasonal allergic rhinitis. Clin Drug Invest. 2001. № 21. Р. 25–32.

Salmun L.M., Lorber R. 24-Hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis. BMC Fam. Pract. 2002. № 3. Р. 14.

Nayak A.S., Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy. 2001. № 56. Р. 1077–1080.

Berger W.E., Schenkel E.J., Mansfield L.E. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann. Allergy Asthma Immunol. 2002. №89. Р. 485–491.

Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy. 2000. №56. Р. 14–20.

Baena-Cagnini C.E., Berger W.E., Dubuske L.M. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int. Arch. Allergy Immunol. 2003. № 130. Р. 307–313.

Ring J., Hein R., Gauger A., Bronsky E., Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebocontrolled study. Int. J. Dermatol. 2001. № 40. Р. 72–76.

Monroe E., Finn A., Patel P., Guerrero R., Ratner P., Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J. Am. Acad. Dermatol. 2003. № 48. Р. 535–541.

DuBuske L.M. Review of desloratadine for the treatment of allergic rhinitis, chronic idiopatic urticaria and allergic inflammatory disorders. Expert Opin. Pharmacother. 2005. № 6(14). Р. 2511–23.

Вousquet J., Bachert C., Canonica G.W. ACCEPT-2 Study Group. Efficacy of desloratadine in persistent allergic rhinitis – a GA2LEN study. Int. Arch. Allergy Immunol. 2010. № 153(4). Р. 395–402.

González-Núñez V., Valero A., Mullol J. Safety evaluation of desloratadine in allergic rhinitis. Expert Opin Drug Saf. 2013 № 12 (3). Р. 445–53.

Clellan K.Mc., Jarvis В. Desloratadine. Drugs. 2001. № 61 (6). Р. 789–96.

Iriarte Sotés Р., Armisén М., Usero-Bárcena Т. Up-Dosing Antihistamines in Chronic Spontaneous Urticaria: Efficacy and Safety. A Systematic Review of the Literature. J Investig Allergol Clin Immunol. 2020.

Nakamura Т., Hiraoka К., Ryuichi H. Brain histamine H 1 receptor occupancy after oral administration of desloratadine and loratadine. Pharmacol Res Perspect. 2019. № 12. 7(4).

Сміян О.І., Бинда Т.П. Застосування Едему у комплексній терапії алергічних захворювань. Здоров’я України. 2014. № 4(39). С. 35–38.

Буряк В.Н., Пошехонова Ю.В., Шабан Н.И., Дудко М.В., Скачкова Л.П., Бессараб П.А. Опыт оптимизации патогенетической терапии атопического дерматита в детском возрасте. Здоровье ребенка. 2011. № 4(31). С. 32–37.

Bagheri H., Simiand E. Adverse Drug Reactions to Anthelmintics. Annals of Pharmacotherapy. 2004. № 38 (3). P. 383–388.

Крамарьов С.О., Закордонець Л.В. Гельмінтози в дітей: підходи до лікування. Здоров’я дитини. 2018. Т. 13, № 3.